Is the in vivo dosimetry with the OneDosePlusTM system able to detect intra-fraction motion? A retrospective analysis of in vivo data from breast and prostate patients
| Autor: | Marco Maria D'Andrea, Alessia Lo Bosco, Mauro Rebuzzi, Riccardo Santoni, Rosaria Barbarino, Maria Daniela Falco, Grazia Tortorelli, Luana Di Murro, Elisabetta Ponti, Barbara Tolu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Male
lcsh:Medical physics. Medical radiology. Nuclear medicine Movement lcsh:R895-920 medicine.medical_treatment Breast Neoplasms OneDosePlusTM system lcsh:RC254-282 In vivo dosimetry Prostate cancer Settore MED/36 - Diagnostica per Immagini e Radioterapia Prostate In vivo medicine Retrospective analysis Humans Dosimetry Radiology Nuclear Medicine and imaging Radiometry business.industry Radiotherapy Planning Computer-Assisted Research Prostatic Neoplasms Radiotherapy Dosage lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease MOSFET detector Radiation therapy medicine.anatomical_structure Oncology Radiology Nuclear Medicine and imaging Intra-fraction motion error Female Nuclear medicine business |
| Zdroj: | Radiation Oncology, Vol 7, Iss 1, p 97 (2012) Radiation Oncology (London, England) |
| Popis: | Background The OneDosePlusTM system, based on MOSFET solid-state radiation detectors and a handheld dosimetry reader, has been used to evaluate intra-fraction movements of patients with breast and prostate cancer. Methods An Action Threshold (AT), defined as the maximum acceptable discrepancy between measured dose and dose calculated with the Treatment Planning System (TPS) (for each field) has been determined from phantom data. To investigate the sensitivity of the system to direction of the patient movements, fixed displacements have been simulated in phantom. The AT has been used as an indicator to establish if patients move during a treatment session, after having verified the set-up with 2D and/or 3D images. Phantom tests have been performed matching different linear accelerators and two TPSs (TPS1 and TPS2). Results The ATs have been found to be very similar (5.0% for TPS1 and 4.5% for TPS2). From statistical data analysis, the system has been found not sensitive enough to reveal displacements smaller than 1 cm (within two standard deviations). The ATs applied to in vivo treatments showed that among the twenty five patients treated for breast cancer, only four of them moved during each measurement session. Splitting data into medial and lateral field, two patients have been found to move during all these sessions; the others, instead, moved only in the second part of the treatment. Patients with prostate cancer have behaved better than patients with breast cancer. Only two out of twenty five moved in each measurement session. Conclusions The method described in the paper, easily implemented in the clinical practice, combines all the advantages of in vivo procedures using the OneDosePlusTM system with the possibility of detecting intra-fraction patient movements. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|